Surveys evaluating plasma lipid goal attainment in patients with coronary heart disease (CHD) show that hypercholesterolemia is inadequately treated. CEPHEUS (CEntralized Pan-European survey on tHE Undertreatment of hypercholeSterolemia)-Greece was part of a European multicenter, cross-sectional survey to evaluate the proportion of patients on lipid-lowering drugs (LLDs) for ≥3 months, without dose modifications for at least 6 weeks, who reach their low-density lipoprotein—cholesterol (LDL-C) target. A total of 1321 Greek patients comprised the full analysis set (FAS); 28% were smokers, while 60.7%, 35.4%, 32.1%, and 25.1% had a history of hypertension, CHD, metabolic syndrome, and diabetes mellitus, respectively; 49.7% of the study population reached the Third Joint European Task Force (TJETF) LDL-C goals and 49.3% achieved the 2004-updated National Cholesterol Education Program Adult Treatment Panel III (NCEP ATPIII) targets. Hypercholesterolemia is suboptimally managed in Greece, with almost 50% of patients on LLDs not reaching the LDL-C target.
British Heart Foundation.European Cardiovascular Disease Statistics. London, UK: British Heart Foundation; 2005.
2.
British Heart Foundation.European Cardiovascular Disease Statistics. London, UK: British Heart Foundation; 2008.
3.
WHO.European Health for All Database . 2008.
4.
Baigent C., Keech A., Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-1278.
5.
Ridker PM, Danielson E., Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195-2207.
6.
LaRosa JC , Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352(14):1425-1435.
7.
Rosenson RSStatins: can the new generation make an impression? Expert Opinion Emerg Drugs. 2004;9(2):269-279.
8.
Graham I., Atar D., Borch-Johnsen K., Boysen G., et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur J Cardiovasc Prev Rehabil. 2007;14(Suppl 2):E1-E40.
9.
Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation . 2004;110(2): 227-239.
10.
Rydén L., Standl E., Bartnik M., et al. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Guidelines on diabetes, pre-diabetes and cardiovascular diseases: executive summary. Eur Heart J. 2007; 28(1):88-136.
11.
Cannon C., Braunwald E., McCabe C., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ;350(15):1495-1504.
12.
Maruthur NM , Wang NY, Appel LJLifestyle interventions reduce coronary heart disease risk. Results from the PREMIER trial. Circulation.2009;119(15):2026-2031.
13.
Iglseder B. , Moroder T., Staffen W., Ladurner G.High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in Austria. Clin Drug Investig. 2005;25(11):709-717.
14.
Diamantopoulos EJ, Athyros VG, Yfanti GK, et al; OLYMPIC Study Group. The control of dyslipidemia in outpatient clinics in Greece (OLYMPIC) Study. Angiology. 2005;56(6): 731-741.
15.
Malik S., Lopez V., Chen R., Wu W., Wong NDUndertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007;77(1):126-133.
16.
Klingman D. , Williams SA, Benner JS, Smith TW, Ahn J., O’Donnell JCGauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J.2005;150(3):595-601.
17.
Kotseva K., Wood D., De Backer G., et al; EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet.2009;373(9667):929-940.
18.
Pearson TA, Laurora I., Chu H., Kafonek S.The Lipid Treatment Assessment project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidaemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000;160(4):459-467.
19.
Waters DD, Brotons C., Chiang CW, et al. Lipid treatment assessment project 2. A multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals. Circulation.2009;120(1):28-34.
20.
Lehane E., McCarthy G.Medication non-adherence-exploring the conceptual mire. Int J Nurs Pract.2009;15(1):25-31.
21.
Liberopoulos EN, Florentin M., Mikhailidis DP, Elisaf MSCompliance with lipid-lowering therapy and its impact on cardiovascular morbidity and mortality . Expert Opin Drug Saf. 2008; 7(6):717-725.
22.
Penning-van Beest FJ, Termorshuizen F., Goettsch WG, et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J.2007;28(2):154-159.
23.
Simons LA, Levis G., Simons J.Apparent discontinuation rates in patients prescribed lipid lowering drugs . Med J Aust. 1996; 164(4):208-211.
24.
Smith DA, Harnick D., Kilaru R.Comparison of physician-managed lipid-lowering care in patients with coronary heart disease in two time periods (1994 and 1999). Am J Cardiol.2001; 88(12):1417-1419.
25.
Davidson MH , Maki KC, Pearson TA, et al. Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations. Am J Cardiol . 2005; 96(4):556-563.
26.
Hatzitolios AI, Athyros VG, Karagiannis A., et al; IMPROVE Collaborative Group. Implementation of strategy for the management of overt dyslipidemia: The IMPROVE-dyslipidemia study. Int J Cardiol.2009;134(3):322-329.
27.
Daskalopoulou SS, Doonan RJ, Mikhailidis DPUndertreatment of hypercholesterolemia . Curr Med Res Opin.2010; 26(2):439-443.
28.
Hermans MP, Castro Cabezas M., Strandberg T., et al. Centralised pan-European survey on the under-treatment of hypercholesterolemia in patients using lipid lowering drugs (CEPHEUS). Value Health . 2007;10(6):PCV68.
29.
Osterberg L. , Blaschke T.Adherence to medication. N Engl J Med. 2005;353(5):487-497.
30.
Dunbar-Jacob J., Erlen JA, Schlenk EA, Ryan CM, Sereika SM, Doswell WMAdherence in chronic disease. Annu Rev Nurs Res.2000 ;18:48-90.
31.
McDonnell PJ , Jacobs MRHospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother. 2002; 36(9):1331-1336.
32.
Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs and frequency of adverse drug events in a health care network. Am J Health System Pharmacy . 2001; 58(12):1126-1132.
33.
Brookhart MA , Patrick AR, Schneeweiss S., et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167(8):847-852.
34.
The West of Scotland Coronary Prevention Study Group.Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J.1997;18(11):1718-1724.
35.
Blackburn DF , Dobson RT, Blackburn JL, Wilson TWCardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25(8):1035-1043.
36.
Rasmussen JN , Chong A., Alter DARelationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction . JAMA. 2007;297(2):177-186.
37.
Chimonas T. , Athyros VG, Ganotakis E., et al; Assessing the Treatment Effect in Metabolic Syndrome Without Perceptible diabeTes (ATTEMPT) Collaborative Group. Cardiovascular risk factors and estimated 10-year risk of fatal cardiovascular events using various equations in Greeks with metabolic syndrome. Angiology.2010;61(1):49-57.
